top of page

- Dec 27, 2023

Cytokinetics’ CEO Robert Blum discusses today’s SEQUOIA-HCM P3 result

Robert Blum describes Aficamten’s topline safety, efficacy, and how the company views its competitive profile.

Recent Posts

In addition to presenting data at ESMO positioning its PD1 as potentially the standard of care in a new indication, Incyte thinks it has an important new drug in its CDK2 inhibitor

Bicycle Therapeutics CEO Kevin Lee highlights the company's data at the 2024 ESMO Congress

The founder of Entos Pharmaceuticals describes trying to design a delivery vehicle that's better than AAV and LNPs by harnessing fusogens

Comments

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

bottom of page